Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation

Bone Marrow Transplantation volume 45, pages 1534–1539 (2010)Cite this article

Subjects

Abstract

Allogenic haematopoietic stem cell transplantation (HCT) has become an effective therapy in patients with various haematological malignancies. GvHD is known to be a major complication in this patient group and is assumed to have a major impact on patients’ quality of life (QOL). Patients after BMT or transplantation of mobilized PBSCs were considered for enrolment in the study 6 months after transplantation. QOL and symptom burden were assessed using the EORTC QLQ-C30 and the QLQ-HDC29. Data from age- and sex-matched healthy controls were collected for comparison. In all, 100 patients (55.0% women; mean age 46.3 years) after allogeneic HCT were included in the study. In this patient group, we found a clinically relevant impact of GvHD on role functioning, global QOL, fatigue, dyspnoea, gastrointestinal side effects, worries/anxiety and skin problems. In comparison to healthy controls, various aspects of QOL were severely impaired. Our study revealed severe impairments of QOL in survivors of HCT, in particular in those suffering from GvHD. Taking into account, that the prevalence of GvHD might be higher in patients after PBSCT compared with patients after BMT, PBSCT is expected to lead to more severe impairments of QOL than BMT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Moog R . Mobilization and harvesting of peripheral blood stem cells. Curr Stem Cell Res Ther 2007; 1: 189–201.

    Article  Google Scholar 

  2. Arai S, Klingemann HG . Hematopoietic stem cell transplantation: bone marrow vs mobilized peripheral blood. Arch Med Res 2003; 34: 545–553.

    Article  CAS  PubMed  Google Scholar 

  3. Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker E et al. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 2004; 10: 405–414.

    Article  PubMed  Google Scholar 

  4. Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R . Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr. Eur J Haematol 2004; 72: 381–389.

    Article  PubMed  Google Scholar 

  5. De Souza C, Duraes M, Vigorito A, Aranha F, Oliveira G, De Brito Eid K et al. Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft. Haematologica 2002; 87: 1281–1285.

    PubMed  Google Scholar 

  6. Velikova G, Weis J, Hjermstad MJ, Kopp M, Morris P, Watson M et al. The EORTC QLQ-HDC29: a supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation. Eur J Cancer 2007; 43: 87–94.

    Article  CAS  PubMed  Google Scholar 

  7. Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M et al. Normative data for functional assessment of cancer therapy—general scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 2004; 43: 153–160.

    Article  PubMed  Google Scholar 

  8. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.

    Article  CAS  PubMed  Google Scholar 

  9. Osoba D, Rodrigues G, Myles J, Zee B, Pater J . Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–144.

    Article  CAS  PubMed  Google Scholar 

  10. Fayers P, Machin D . Quality of Life: Assessment, Analysis and Interpretation. J Wiley & Sons: Chichester, 2000.

    Book  Google Scholar 

  11. Kopp M, Holzner B, Meraner V, Sperner-Unterweger B, Kemmler G, Nguyen-Van-Tam Dominic P et al. Quality of life in adult hematopoietic cell transplant patients at least 5 yr after treatment: a comparison with healthy controls. Eur J Haematol 2005; 74: 304–308.

    Article  PubMed  Google Scholar 

  12. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074–5087.

    Article  Google Scholar 

  13. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA . Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20: 2334–2343.

    Article  CAS  PubMed  Google Scholar 

  14. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ et al. Quality of life associated with acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2006; 38: 305–310.

    Article  CAS  Google Scholar 

  15. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin J . Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria

    S Pallua, J Giesinger, A Oberguggenberger, G Kemmler, M Kopp, B Sperner-Unterweger & B Holzner

  2. Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria

    D Nachbaur & J Clausen

Authors
  1. S Pallua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Giesinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Oberguggenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Kemmler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Nachbaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Clausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Kopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Sperner-Unterweger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B Holzner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Holzner.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pallua, S., Giesinger, J., Oberguggenberger, A. et al. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant 45, 1534–1539 (2010). https://doi.org/10.1038/bmt.2010.5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.5

Keywords

Search

Advanced search

Quick links